Former President Joe Biden’s diagnosis of aggressive prostate cancer has sparked a conversation about the importance of prostate cancer prevention and screening. The U.S. Preventive Services Task Force advises men between 55 and 69 years old to talk with their healthcare providers about the pros and cons of PSA screening and then decide individually. For men over 70, the recommendation is to forgo screenings altogether. Dr. Shawn Dason, a urologic oncologist, highlights that while the USPSTF is a common guideline, other organizations have different recommendations, emphasizing that men in their 50s and 60s should have these discussions with their doctors.
Dr. Dason underscores the necessity for men in their 50s and 60s to engage in discussions with healthcare providers about prostate cancer and PSA screening. They need to weigh the benefits and potential harms together, ensuring they make informed decisions. The risk of screening includes possible overtreatment or unnecessary procedures, especially for men under 50 and over 70, due to varying guidelines.
In the past, the understanding of when to treat prostate cancer was less nuanced. Now, there is a protocol called “active surveillance” that allows doctors to monitor the cancer closely instead of jumping to immediate treatment. This approach helps avoid the side effects of treatment, which can include urinary, sexual, or bowel issues. As Dr. Dason points out, some men might be over-treated for prostate cancer that would not have caused death or serious health problems.
The use of PSA screening has decreased among men over the age of 40, partly due to the USPSTF recommendation, according to one doctor. This decline in screening has raised concerns since prostate cancer diagnoses continue to occur at significant rates in the U.S. The doctor warns that treatment might sometimes be more harmful than the impacts of the cancer itself, especially if the cancer is unlikely to cause death.
Dr. Marc Siegel, Fox News’ senior medical analyst, has expressed his concerns about the lack of routine screening recommendations for men over 70. He has pointed out that prostate cancer remains a significant issue, with over 300,000 new cases and 35,000 deaths annually in the U.S. Siegel advocates for screening all men over 45, arguing that advancements in treatment now lead to fewer side effects.
There’s a strong argument that all men over 45 should undergo screening, regardless of age, due to improved treatment options, says Dr. Siegel. He suggests that a high-profile individual, like a president, should receive aggressive screenings due to their status, but insists that average-risk men without symptoms should also be screened. This approach could potentially prevent many deaths by catching cancer early.
Dr. Dason agrees that some men over 70 are suitable for screening, particularly if they are in good health and have a reasonable life expectancy. For these individuals, detecting a serious prostate cancer could significantly impact their lifespan or quality of life. However, those with existing health issues and limited life expectancy might endure more harm than benefit from screening.
Men should consider their health status and discuss their options with healthcare providers, Dr. Dason advises. The decision to screen should be personalized, taking into account individual circumstances and potential outcomes. This personalized approach ensures that each man receives the best possible advice based on his situation.
The conversation around prostate cancer screening continues to evolve as new data and treatment options emerge. Men are encouraged to stay informed and proactive about their health, engaging in open dialogues with their medical providers. Such discussions can lead to better outcomes and more personalized healthcare decisions.
